A phase II trial evaluating the efficacy and safety of repeated high dose medroxyprogesterone acetate (MPA) therapy for patients with recurrent early-stage endometrial cancer or atypical endometrial hyperplasia: Japanese Gynecologic Oncology Group study (JGOG2051/KGOG2031, REMPA trial)-Reference-Cited by-同舟云学术

A phase II trial evaluating the efficacy and safety of repeated high dose medroxyprogesterone acetate (MPA) therapy for patients with recurrent early-stage endometrial cancer or atypical endometrial hyperplasia: Japanese Gynecologic Oncology Group study (JGOG2051/KGOG2031, REMPA trial)

Published:2024 Issue: Volume:35 Page:
ISSN:2005-0380
Container-title:Journal of Gynecologic Oncology
language:en
Short-container-title:J Gynecol Oncol

Author:

Sakai Kensuke¹^ORCID,Yamagami Wataru¹^ORCID,Sato Yasunori²^ORCID,Susumu Nobuyuki³^ORCID,Yokoyama Yoshihito⁴^ORCID,Takehara Kazuhiro⁵^ORCID,Mandai Masaki⁶^ORCID,Okamoto Aikou⁷^ORCID

Affiliation:

1. Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.

2. Department of Preventive Medicine and Public Health, Keio University School of Medicine, Tokyo, Japan.

3. Department of Obstetrics and Gynecology, International University of Health and Welfare, Narita, Japan.

4. Department of Obstetrics and Gynecology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

5. Department of Gynecologic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.

6. Department of Obstetrics and Gynecology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

7. Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan.

Funder

Japan Agency for Medical Research and Development

Publisher

XMLink

Link

https://ejgo.org/pdf/10.3802/jgo.2024.35.e106

Reference9 articles.

1. Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual Patient Report for 2018 and Annual Treatment Report for 2013

2. Oncologic and Reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 Adenocarcinoma: A systematic review

3. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis

4. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002)

5. Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology